Can a PET scan predict which breast cancer patients will respond to treatment?
NCT ID NCT06179303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special type of PET scan (FFNP-PET/CT) can predict how well a drug combination (abemaciclib plus hormone therapy) works in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants with metastatic or locally advanced breast cancer will receive the treatment and have imaging before and during therapy. The goal is to see if changes in the scan can tell early on who is responding and who is not, helping doctors personalize treatment in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
-
Siteman Cancer Center at Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?